LLY Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly Plans $8 Billion Bond Sale, Funding Recent Acquisition Spree
Eli Lilly and Co. is seeking to raise approximately $8 billion through an investment-grade bond sale. The drugmaker intends to use the capital for recent and...
Eli Lilly Invests $4.5 Billion More in Indiana for Weight-Loss Drugs
Eli Lilly and Company announced an additional $4.5 billion investment in its Lebanon, Indiana manufacturing facilities. This brings the company's total...
Lilly’s Omvoh Maintains Ulcerative Colitis Clearance Through Four Years
Eli Lilly and Company released long-term data for its ulcerative colitis treatment, Omvoh (mirikizumab-mrkz). The LUCENT-3 open-label extension study tracked...
Pharma Giants Bet Billions on AI, Boosting Efficiency Before Drug Breakthroughs
Eli Lilly, Roche, GSK, and Merck are committing billions of dollars to artificial intelligence partnerships and infrastructure. These companies are building...
Eli Lilly shares drop 3%, following liver failure report for Foundayo
Eli Lilly shares fell approximately 3% on Monday. An Evercore ISI analyst report triggered the decline. The report highlighted a single case of hepatic...
Eli Lilly secures Canadian approval for Kisunla, expanding to 48 markets
Health Canada approved Eli Lilly and Company’s Kisunla (donanemab) for treating early symptomatic Alzheimer's disease. The once-monthly treatment targets...
Eli Lilly Retains Buy Rating, BofA Cites Strong Mounjaro Demand
Bank of America reiterated its Buy rating for Eli Lilly on May 2, 2026. The bank lowered its price target to $1,133 from $1,294. This adjustment reflects a...
Eli Lilly's first quarter 2026 revenue surged 56% on GLP-1 drug sales, leading to a raised full-year outlook.
Eli Lilly reported first-quarter revenue of $19.8 billion, a 56% increase year-over-year, with non-GAAP EPS growing 156% to $8.55. These results were driven by...
Eli Lilly Posts Its Biggest Quarter Ever as Weight-Loss Drugs Surge — But Can Pricing Pressure Keep Up With the Hype?
Shares surged more than 10% as Eli Lilly delivered what CEO Dave Ricks called an unprecedented streak: "Impressively, it's like our fifth or sixth quarter in...
🟢 LLY is trading 10.41% up today after a massive Q1 earnings beat and raised full-year guidance
LLY is trading at $939.84 (+10.41%) following a blockbuster Q1 2026 earnings report and an upward revision to its full-year financial outlook. • The company...
Eli Lilly Shares Soar 9% on Massive Q1 Beat and Raised Outlook
Eli Lilly reported Q1 CY2026 revenue of $19.8 billion. This figure represents 55.5% year-over-year growth. The revenue total beat analyst estimates by...
Eli Lilly and Company Q1 2026 Earnings Preview: What Analysts Expect on April 30, 2026
For the first quarter of 2026, analysts anticipate Eli Lilly and Company to report consensus revenue of approximately $17.78 billion and adjusted earnings of...
Eli Lilly signs $2.25 billion Profluent deal, targeting AI gene editing
Eli Lilly partnered with Profluent on April 28, 2026, to develop AI-driven genetic medicines. The collaboration carries a potential total value of $2.25...
Eli Lilly acquires Ajax Therapeutics for $2.3B, targeting rare blood cancers
Eli Lilly signed a deal to acquire Ajax Therapeutics for up to $2.3 billion. The transaction includes an upfront cash payment and future milestone-based...
Eli Lilly Shares Fall, Zepbound Prescriptions Lag Behind Rival Wegovy
Eli Lilly shares fell 2% in premarket trading on Friday. The decline followed the release of weekly prescription data for the period ending April 17. Total...
🔴 LLY is trading 3.22% down
LLY is trading at $888.07, down 3.22%.
🔴 LLY is trading 3.6% down on Amazon's entry into GLP-1 drug market
LLY is trading at $884.99 (-3.6%) in pre-market action after Amazon announced the launch of a new GLP-1 obesity drug program, creating a significant new...
🔴 LLY is trading 3% down today amid sector volatility and geopolitical tensions
LLY is trading at $889.81 (-3.03%) in pre-market action on April 24, 2026, following a close of $917.65 the previous day. The decline occurs despite a lack of...
Eli Lilly Expands Telehealth Reach for Zepbound Through Hims & Hers Platform
Hims & Hers expanded its platform functionality. Healthcare providers can now prescribe Eli Lilly’s weight-loss drug Zepbound in vials and KwikPen formats to...
Eli Lilly Shares Slide, Driven by CVS Medicare Obesity Model Exit
Eli Lilly shares fell as much as 3.8% after CVS Health opted out of a Medicare model for obesity medications. [7, 8] The decision threatens market penetration...